Merck, 288104-1MG, 2′,5′-Dideoxyadenosine

General description
Cell-permeable, non-competitive adenylate cyclase inhibitor (IC₅₀ = 3 µM), that binds to the adenosine P1 binding site. Blocks positive inotropic and chronotropic effects of β-adrenergic agents.
Membrane-permeable adenylate cyclase inhibitor that binds non-competitively to the enzyme via the P-site. Its inhibitory effect varies widely among tissues (IC₅₀ = 3 µM for detergent solubilized rat brain membranes; IC₅₀ = 45 µM for purified bovine brain enzyme). Blocks the forskolin-induced activation of adenylate cyclase activity (IC₅₀ = 540 µM) in cultured bovine aortic endothelial cells. Also blocks the positive ionotropic and chronotropic effects of β-adrenergic agents.
Biochem/physiol Actions
Cell permeable: yes
Product does not compete with ATP.
Reversible: no
Target IC₅₀: 3 µM against adenylate cyclase
Other Notes
Ibrahimi, A., et al. 1999. Am. J. Physiol.276, C487.
Hartman, M., and Schrader, J. 1995. J. Mol. Cell. Cardiol. 25, 331.
Bushfield, M., et al. 1990. Mol. Pharmacol.38, 848.
Reid, I.R., et al. 1990. Am. J. Physiol.258, E708.
Legrand, A.B., et al. 1990. Biochem. Pharmacol.40, 1103.
Johnson, R.A., et al. 1989. Mol. Pharmacol.35, 681.
Holgate, S.T., et al. 1980. Proc. Natl. Acad. Sci. USA77, 6800.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)